In our exclusive interview, Aditya Bardia, MD, discusses the FDA approval of sacituzumab govitecan (Trodelvy) in metastatic triple-negative breast cancer.
FDA Approval Insights
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
2
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
3
Five Under 5: Top Oncology Videos for the Week of 9/27
4
AUA Releases Guideline Amendment for NMIBC
5